Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Evaluation of the Anti-Tumor Effects of an Anti-Human Epidermal Growth Factor Receptor 2 (Her2) Monoclonal Antibody in Combination With Cd11b+/Gr-1+ Myeloid Cells Depletion Using a Recombinant Peptibody in 4 T1-Her2 Tumor Model Publisher Pubmed



Ramezanialiakbari K1 ; Khakibakhtiarvand V1 ; Mahmoudian J2 ; Asgarianomran H3 ; Shokri F4 ; Hojjatfarsangi M5 ; Jedditehrani M2 ; Shabani M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
  3. 3. Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  4. 4. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna and Karolinska Institute, Stockholm, 17164, Sweden

Source: International Immunopharmacology Published:2023


Abstract

Introduction: Clinical efficacy of Human Epidermal growth factor Receptor 2 (HER2) targeted strategies is limited due to impaired anti-tumor responses negatively regulated by immunosuppressive cells. We thus, investigated the inhibitory effects of an anti-HER2 monoclonal antibody (1 T0 mAb) in combination with CD11b+/Gr-1+ myeloid cells depletion in 4 T1-HER2 tumor model. Methods: BALB/c mice were challenged with human HER2-expressing 4 T1 murine breast cancer cell line. A week post tumor challenge, each mouse received 50 µg of a myeloid cells specific peptibody every other day, or 10 mg/kg of 1 T0 mAb two times a week, and their combination for two weeks. The treatments effect on tumor growth was measured by calculating tumor size. Also, the frequencies of CD11b+/Gr-1+ cells and T lymphocytes were measured by flow cytometry. Results: Peptibody treated mice indicated tumor regression and 40 % of the mice eradicated their primary tumors. The peptibody was capable to deplete notably splenic CD11b+/Gr-1+ cells as well as intratumoral CD11b+/Gr-1+ cells (P < 0.0001) and led to an increased number of tumor infiltrating CD8+ T cells (3.3 folds) and also that of resident tumor draining lymph nodes (TDLNs) (3 folds). Combination of peptibody and 1 T0 mAb resulted in enhanced expansion of tumor infiltrating CD4 + and CD8+ T cells which was associated with tumor eradication in 60 % of the mice. Conclusions: Peptibody is able to deplete CD11b+/Gr-1+ cells and increase anti-tumoral effects of the 1 T0 mAb in tumor eradication. Thus, this myeloid population have critical roles in development of tumors and their depletion is associated with induction of anti-tumoral responses. © 2023
Other Related Docs
13. New Insights Into Affinity Proteins for Her2-Targeted Therapy: Beyond Trastuzumab, Biochimica et Biophysica Acta - Reviews on Cancer (2020)
22. Myeloid-Derived Suppressor Cells in Gastrointestinal Cancers: A Systematic Review, Journal of Gastroenterology and Hepatology (Australia) (2016)
24. Tumor Immunology, Clinical Immunology (2022)
33. Roles of Myeloid-Derived Suppressor Cells in Cancer Metastasis: Immunosuppression and Beyond, Archivum Immunologiae et Therapiae Experimentalis (2019)
35. Melatonin for Gastric Cancer Treatment: Where Do We Stand?, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
36. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)